An archive of ADCC/CDC-enhanced biobetter antibodies developed by Creative Biolabs' state-of-the-art technology platform.
ADCC-Enhanced Biobetter is a class of therapeutic biological antibodies that are not fucosylated. Creative Biolabs has an advanced Afuco™ technology platform that can control the glycosylation level of antibodies, achieving ADCC enhancement by reducing fucosylation in the Fc region of the antibody. This class of antibodies is a biological drug that increases the binding affinity of the FcyR receptor to immune effector cells. More specifically, DNA recombinant technology is used to produce this fucosylated therapeutic ADCC-Enhanced. It is produced in CHO cells lacking fucosylation and purified by affinity chromatography of protein G.
Please search below for your ADCC-Enhanced Biobetter antibody of interest. Or contact us directly to tailor a solution to your specific needs.
Biobetter Antibodies Betting on the Future Creative Biolabs Visit
All products and services are for Research Use Only. Do Not use in humans.